New scalp treatment for hair loss under study
NCT ID NCT07402330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a drug called DA-020 in 60 healthy women aged 18-55. The goal is to measure how much of the drug enters the blood after one application to the scalp and to check for side effects like blood pressure changes. This research helps understand the drug's safety before testing it in people with hair loss from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Samel
Manaus, Brazil
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rome ("G. Marconi")
Rome, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••